<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715247</url>
  </required_header>
  <id_info>
    <org_study_id>17793</org_study_id>
    <secondary_id>1P01CA10867101A2</secondary_id>
    <nct_id>NCT00715247</nct_id>
  </id_info>
  <brief_title>Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF &amp; ET Genes</brief_title>
  <official_title>Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF &amp; ET Genes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myeloproliferative Disorders-Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to find genes whose mutations cause Polycythemia Vera,
      Essential Thrombocythemia and Primary Myelofibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), also
      known as the Philadelphia Chromosome negative myeloproliferative disorders (MPDs), are not
      congenital, but acquired. The purpose of this project is to find genes whose mutations cause
      these disorders, as well as improve diagnostic measures for these diseases. When this is
      accomplished new therapies to control and eventually cure the disease can be designed.

      All subjects will be asked to donate 4-6 teaspoons of blood. On occasion, if the blood cells
      from a particular sample do not grow well and the DNA from that sample is used up or other
      tests are needed, we may ask to collect additional samples. In patients who have undergone a
      bone marrow biopsy as part of their clinical evaluation, we will test the reproducibility
      between pathologists for the revised 2008 WHO diagnostic criteria to diagnose
      myeloproliferative disorders (MPD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if there are proteins expressed by cells from patients that might be targets for the immune response.</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Affected Population</arm_group_label>
    <description>Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Female Controls</arm_group_label>
    <description>Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and bone marrow aspirate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suspected to have one of the following blood disorders: polycythemia vera,
        myelofibrosis or essential thrombocythemia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with an elevated hemoglobin concentration (&gt;18 in males and &gt;16 in females)
             and who are suspected to have congenital or acquired primary polycythemia

          2. Patients with a persistent thrombocytosis (&gt;400,000) that does not have an obvious
             secondary cause

          3. Patients with a bone marrow biopsy that shows increased cellularity and fibrosis

          4. Patients where there is clinical concern for primary myelofibrosis, such as anemia in
             combination with leukocytosis, thrombocytosis, splenomegaly and/or a
             leukoerythroblastic blood smear

          5. Patients with thrombosis at unusual sites, such as Budd-Chiari syndrome, can have
             early PV before hemoglobin is elevated, these patients will also be included.

        Exclusion Criteria:

          1. Subjects who have a known acquired cause of polycythemia (increased
             hemoglobin/hematocrit) such as people living in high altitudes (in excess of 14,000
             feet), subjects with heart disease, left to right heart shunt, severe hypoxia or
             severe pulmonary disease will be excluded from this study.

          2. Subjects with a known acquired cause of thrombocytosis.

          3. Subjects will be excluded if they cannot demonstrate decision making capacity
             sufficient to agree or decline the blood drawing or use of their blood for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef T Prchal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josef T Prchal, MD</last_name>
    <phone>801-581-4220</phone>
    <email>josef.prchal@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Hickman, BS</last_name>
    <phone>801-581-3707</phone>
    <email>kimberly.hickman@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef T Prchal, MD</last_name>
      <phone>801-581-4220</phone>
      <email>josef.prchal@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Hickman, BS</last_name>
      <phone>801-581-3707</phone>
      <email>kimberly.hickman@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neeraj Agarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Salama, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Archana Agarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Kelley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurizio Zangari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Deininger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabina Swierczek, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpd-rc.org</url>
    <description>Myeloproliferative Disorders Research Consortium</description>
  </link>
  <reference>
    <citation>Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V. Epigenetic control of PRV-1 expression on neutrophils. Exp Hematol. 2007 Nov;35(11):1677-83.</citation>
    <PMID>17976520</PMID>
  </reference>
  <reference>
    <citation>Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci. 2007 Oct 4;4(4):232-6.</citation>
    <PMID>17952198</PMID>
  </reference>
  <reference>
    <citation>Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Jun;35(6):931-8.</citation>
    <PMID>17533047</PMID>
  </reference>
  <reference>
    <citation>Chen GL, Prchal JT. X-linked clonality testing: interpretation and limitations. Blood. 2007 Sep 1;110(5):1411-9. Epub 2007 Apr 13. Review.</citation>
    <PMID>17435115</PMID>
  </reference>
  <reference>
    <citation>Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol. 2007 Apr;35(4):587-95.</citation>
    <PMID>17379069</PMID>
  </reference>
  <reference>
    <citation>Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72. Review.</citation>
    <PMID>17222772</PMID>
  </reference>
  <reference>
    <citation>Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF, Prchal JT. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007 Jan;35(1):32-8.</citation>
    <PMID>17198871</PMID>
  </reference>
  <reference>
    <citation>Chen GL, Liu E, Naidoo K, Popat U, Coetzer TL, Prchal JT. Idiopathic myelofibrosis without dacryocytes. Haematologica. 2006 Jun;91(6 Suppl):ECR29.</citation>
    <PMID>16785132</PMID>
  </reference>
  <reference>
    <citation>Finazzi G, Gregg XT, Barbui T, Prchal JT. Idiopathic erythrocytosis and other non-clonal polycythemias. Best Pract Res Clin Haematol. 2006;19(3):471-82. Review.</citation>
    <PMID>16781484</PMID>
  </reference>
  <reference>
    <citation>Chen G, Prchal JT. Polycythemia vera and its molecular basis: an update. Best Pract Res Clin Haematol. 2006;19(3):387-97. Review.</citation>
    <PMID>16781479</PMID>
  </reference>
  <reference>
    <citation>Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood. 2006 May 1;107(9):3486-8. Epub 2006 Jan 17.</citation>
    <PMID>16418333</PMID>
  </reference>
  <reference>
    <citation>Skoda R, Prchal JT. Chronic myeloproliferative disorders--introduction. Semin Hematol. 2005 Oct;42(4):181-3. Review.</citation>
    <PMID>16210031</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>Hematological Malignancies</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Genetics</keyword>
  <keyword>Chronic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

